How AI and Machine Learning Are Transforming Life Sciences in Switzerland — And What Your Organisation Needs to Know

The AI Inflection Point in Pharma and Healthcare

The pharmaceutical and life sciences sectors are no longer simply adopting artificial intelligence — they are being reshaped by it. From drug discovery accelerated by machine learning models to AI-assisted clinical trial design and real-world evidence generation, the pace of change is unlike anything the industry has seen in decades.

For organisations operating in Switzerland and the EU, this shift represents both a profound opportunity and a significant delivery challenge. Capturing the value of AI in life sciences requires more than a technology investment. It demands the right strategy, the right talent, and — critically — a change management approach that brings people along on the journey.

Why AI in Life Sciences Is Different from Every Other Industry

Healthcare and pharma operate under constraints that most industries simply do not face: GxP compliance requirements, regulatory frameworks from Swissmedic and the EMA, patient safety obligations, and the complexity of clinical data governance.

AI in pharma is therefore not a plug-and-play proposition. A machine learning model predicting compound efficacy must be explainable. A GenAI tool used in regulatory submissions must be validated. A clinical decision support system must be auditable.

Organisations that treat AI in life sciences as a standard IT project — ignoring the regulatory, compliance and change dimensions — consistently underdeliver on ROI.

At ANG Associates, we have spent over 15 years working at the intersection of healthcare technology and delivery management. We understand that in this sector, the "how" of AI implementation matters as much as the "what."

Key AI Use Cases Transforming Pharma and Diagnostics Today

AI-Accelerated Drug Discovery and R&D

Machine learning is compressing timelines in early-stage drug discovery. By training models on molecular structures, biological pathways and existing compound libraries, AI enables researchers to identify viable candidates faster and with greater precision. For Swiss pharma companies — many of whom operate some of the world's most advanced R&D pipelines — this translates into a measurable competitive edge.

Clinical Trials Optimisation

AI models are improving patient recruitment and stratification for clinical trials, reducing dropout rates and accelerating time-to-result. GenAI tools are being used to synthesise clinical documentation, generate protocol summaries and flag data anomalies in real time.

Real-World Evidence and Data Analytics

Regulatory agencies are increasingly accepting Real-World Evidence (RWE) as part of submissions. AI-powered analytics platforms can extract structured insights from unstructured real-world data at scale — giving pharmacovigilance and HEOR teams capabilities that were previously out of reach.

GxP-Compliant AI Governance

As AI moves closer to regulated environments, organisations need frameworks for responsible AI use — covering model validation, audit trails, explainability and bias mitigation. Building these governance structures requires cross-functional expertise spanning IT, quality, regulatory affairs and change management.

The Delivery Gap: Why Most Life Sciences AI Projects Underperform

Studies consistently show that while over 90% of large organisations have adopted cloud infrastructure, fewer than a third achieve their anticipated ROI from AI initiatives. The gap is rarely a technology problem. It is almost always a people, process and delivery problem.

In our work with life sciences clients across Switzerland and the EU, we see the same failure patterns:

• AI projects scoped as technology deployments, not business transformation programmes
• Lack of alignment between IT delivery teams and domain experts (clinical, regulatory, commercial)
• Change management treated as an afterthought rather than a design principle
• No Lean Portfolio Management to prioritise AI initiatives against strategic value

Our approach is different. We believe that cloud is the enabler, data is the driver, and AI is the differentiator — and that unlocking AI's true value in life sciences requires integrating delivery excellence with deep industry expertise.

Our Approach: Integrated AI Delivery for Life Sciences

Agile and SAFe Delivery for AI Programmes

Large AI transformation programmes in life sciences benefit from Scaled Agile (SAFe) frameworks that align multiple teams, manage dependencies, and deliver value incrementally. ANG Associates offers SAFe coaching and implementation tailored specifically to pharma and diagnostics organisations, including SAFe Scrum Masters, Release Train Engineers, and Programme Consultants.

Lean Portfolio Management

With multiple AI initiatives competing for investment, our Business Value (BV) model helps life sciences portfolio teams cut through complexity and focus resources on the initiatives most likely to deliver strategic impact. This is especially critical in organisations where IT, R&D, commercial and compliance teams all have competing priorities.

AI and Machine Learning Implementation

From strategy and use case identification through to model deployment and monitoring, ANG Associates provides end-to-end AI and ML implementation services. We bring the cross-functional expertise — data science, engineering, regulatory, change management — required to deliver AI safely and sustainably in GxP environments.

Data Analytics and Governance

Quality AI starts with quality data. Our data analytics practice helps life sciences organisations build the data foundations — clean, governed, accessible — that make AI investments worthwhile. We specialise in mobilising fragmented data assets and building the analytics capabilities needed for both operational insight and regulatory submission.

Human-First AI Transformation: The Change Management Dimension

Perhaps the most overlooked dimension of AI adoption in life sciences is the human one. Researchers, clinicians, regulatory specialists and commercial teams must not just be trained to use new AI tools — they must understand why those tools exist and how they create value for patients, the business and the broader healthcare ecosystem.

ANG Associates leads with a human-first change management philosophy. We do not simply teach people how to use something; we help them understand why they are using it. This approach drives higher adoption rates, faster ROI realisation, and organisations that are genuinely transformed — not just technically upgraded.

Why Switzerland-Based Life Sciences Organisations Choose ANG Associates

• 15+ years of life sciences and healthcare IT expertise across pharma, diagnostics and digital health
• Swiss-based with EU reach — we understand the regulatory landscape of Swissmedic, the EMA and Swiss data privacy law
• End-to-end delivery capability — from AI strategy and portfolio management through to SAFe coaching, data analytics, and change management
• Dedicated Women in Science & Technology (WRST) programme — bringing diverse, experienced talent in AI, DevOps, UX/UI and agile coaching
• GxP and regulatory awareness embedded in all AI delivery engagements

Getting Started: What Does an AI Readiness Assessment Look Like?

If your organisation is exploring AI adoption or looking to accelerate an existing AI programme, the right starting point is an honest assessment of your current state: your data maturity, your delivery capability, your change readiness and your portfolio prioritisation.

ANG Associates offers structured AI readiness consultations designed specifically for life sciences organisations in Switzerland and the EU. In a focused engagement, we help you:

• Identify the AI use cases with the highest business value
• Assess your data and technology foundations
• Define a delivery roadmap aligned to your regulatory obligations
• Build the change management strategy to ensure adoption

Conclusion

The organisations that will lead in AI-powered life sciences are not those with the biggest technology budgets — they are those that combine strong delivery capability, deep domain expertise, and a commitment to human-centred change.

ANG Associates exists to be that partner for pharma, diagnostics and healthcare organisations across Switzerland and the EU.